Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial

/PRNewswire/ -- Cellenkos® today announced encouraging safety data from its innovative CK0803 neurotrophic T regulatory (Treg) cell therapy, being developed to...

Related Keywords

Houston ,Texas ,United States ,New York ,Baylor College Of Medicine ,Columbia University ,Tara Sadeghi ,Prnewswire Cellenkos ,Cellenkos Inc ,Michaele Debakey Va Medical Center ,National Institute Of Neurological Disorders ,Amyotrophic Lateral Sclerosis ,Data Safety Monitoring Board ,Chief Operating Officer ,Run In Study ,Double Blind ,Placebo Control Trial ,Baylor College ,Rating Scale Revised ,National Institute ,Neurological Disorders ,Cellenkos ,Nc ,